Episode duration and severity as predictors of placebo response in major depressive disorder.
J Affect DisordMay 23, 2026 (epub)
Clinical ResearchPsychiatry
Evyn M Peters, Adetunji Quadri, Saba Aziz et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed the impact of episode duration and severity on placebo response in major depressive disorder across seven studies involving 3,647 participants. It found that both chronicity and severity were linked to lower placebo response rates, but did not influence the efficacy of desvenlafaxine compared to placebo.
Key findings
- Chronicity and severity were associated with lower placebo response rates.
- Neither chronicity nor severity moderated the efficacy of desvenlafaxine over placebo.
- Subgroup-treatment interactions were nonsignificant, indicating no meaningful drug-placebo differences based on these factors.
Why it matters
Understanding the predictors of placebo response can help clinicians interpret clinical trial results and improve patient selection for antidepressant therapies. This study highlights the limitations of using episode duration and severity as criteria for enhancing treatment outcomes.